Mohamadali Amlani, MD
Cardiology · Flint, MINPI 1154385870
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 406 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Among cardiology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 406 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Amgen$1K
- Merck$603
- Johnson & Johnson$575
- E.r. Squibb & Sons, L.L.C.$486
- Pfizer$341
- plus $3K from 26 others
Across 1 payment — averaging $2400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$2K
What the payments were for
- Food & beverage$7,78197%
- Education$2183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 79 | $1,463 |
| Amgen | 61 | $1,397 |
| Merck | 35 | $603 |
| Johnson & Johnson | 35 | $575 |
| E.r. Squibb & Sons, L.L.C. | 32 | $486 |
| Pfizer | 20 | $341 |
| Boehringer Ingelheim | 16 | $323 |
| Sanofi-aventis U.S. LLC | 17 | $322 |
| Actelion Pharmaceuticals US, Inc. | 14 | $295 |
| Boston Scientific | 9 | $274 |
| Astellas Pharma US Inc | 6 | $262 |
| Abbott | 8 | $162 |
| Medtronic(2 entities) | 4 | $148 |
| Kestra Medical Technology Services, Inc. | 7 | $141 |
| Bayer | 6 | $135 |
| Esperion Therapeutics, Inc. | 7 | $127 |
| Vital Connect, Inc | 4 | $122 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $109 |
| Alnylam Pharmaceuticals Inc. | 6 | $106 |
| Regeneron Healthcare Solutions, Inc. | 7 | $98 |
| Novo Nordisk | 5 | $89 |
| Heartflow, Inc. | 4 | $82 |
| AstraZeneca | 5 | $77 |
| Bridgebio Pharma, Inc. | 2 | $53 |
| Lexicon Pharmaceuticals, Inc. | 3 | $50 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $46 |
| Cardiva Medical, Inc. | 1 | $26 |
| Philips North America LLC | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Teleflex LLC | 1 | $19 |
| Cordis US CORP. | 1 | $16 |
| Biotronik Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$126
- Repatha$125
How this compares
$8,000 in reported general payments places this provider in the 95th percentile of 28 cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 377 | $442,307 |
| EntrestoSacubitril/Valsartan | 182 | $218,012 |
| XareltoRivaroxaban | 136 | $131,494 |
| Repatha SureclickEvolocumab | 108 | $118,811 |
| BrilintaTicagrelor | 26 | $26,704 |
| JardianceEmpagliflozin | 18 | $22,707 |
| Praluent PenAlirocumab | 12 | $17,083 |
| Repatha SyringeEvolocumab | 18 | $15,530 |
| Repatha PushtronexEvolocumab | 16 | $12,985 |
| MultaqDronedarone Hcl | 12 | $10,254 |
| Metoprolol Succinate | 574 | $8,871 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 504 | $8,356 |
| Atorvastatin Calcium | 413 | $7,078 |
| Rosuvastatin Calcium | 353 | $6,682 |
| Ranolazine ErRanolazine | 58 | $5,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $341 | $442,307377 claims |
| NovartisEntresto | $1,463 | $218,012182 claims |
| Johnson & JohnsonXarelto | $575 | $131,494136 claims |
| AstraZenecaBrilinta | $77 | $26,70426 claims |
| Boehringer IngelheimJardiance | $323 | $22,70718 claims |
| Sanofi-aventis U.S. LLCMultaq | $322 | $10,25412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 cardiology providers in Michigan.
Other cardiology in Flint
- Ethiraj RajFlint$8K
- Sule SalamiDetroit$6K
- Anubhav JainRochester$4K
- Robert GenoveseMidland$0
- Katherine FellBrighton$0
- Daniel EitzmanAnn Arbor$0
- Daniel McAreeAnn Arbor$0
- Ali MahajerinGrand Rapids$0
- James HeinsimerRoyal Oak$0
- David ForstTroy$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.